Logo image of CSTL

CASTLE BIOSCIENCES INC (CSTL) Stock Price, Quote, News and Overview

NASDAQ:CSTL - Nasdaq - US14843C1053 - Common Stock - Currency: USD

16.2  -0.03 (-0.18%)

CSTL Quote, Performance and Key Statistics

CASTLE BIOSCIENCES INC

NASDAQ:CSTL (5/29/2025, 9:58:36 AM)

16.2

-0.03 (-0.18%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Providers & Services
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Services
Statistics
52 Week High35.84
52 Week Low15.45
Market Cap467.69M
Shares28.87M
Float28.07M
Yearly DividendN/A
Dividend YieldN/A
PE31.15
Fwd PEN/A
Earnings (Next)08-04 2025-08-04/amc
IPO07-25 2019-07-25


CSTL short term performance overview.The bars show the price performance of CSTL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

CSTL long term performance overview.The bars show the price performance of CSTL in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of CSTL is 16.2 USD. In the past month the price decreased by -18.24%. In the past year, price decreased by -30.22%.

CASTLE BIOSCIENCES INC / CSTL Daily stock chart

CSTL Competitors/Peers

The largest stocks on the US markets in the "Health Care Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
CI THE CIGNA GROUP 11.29 83.25B
CVS CVS HEALTH CORP 9.87 79.43B
LH LABCORP HOLDINGS INC 16.77 20.68B
DGX QUEST DIAGNOSTICS INC 18.73 19.22B
FMS FRESENIUS MEDICAL CARE-ADR 15.53 16.77B
BTSGU BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 131.79 14.24B
HIMS HIMS & HERS HEALTH INC 78.1 12.06B
DVA DAVITA INC 14.68 10.24B
CHE CHEMED CORP 24.32 8.39B
CRVL CORVEL CORP 31.32 5.74B
OPCH OPTION CARE HEALTH INC 25.78 5.23B
GH GUARDANT HEALTH INC N/A 4.80B

About CSTL

Company Profile

CSTL logo image Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 761 full-time employees. The company went IPO on 2019-07-25. The Company’s portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-Melanoma is its risk stratification gene expression profile (GEP) test that predicts the likelihood of positive sentinel lymph node and the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM). DecisionDx-SCC is its GEP test for use in patients with cutaneous squamous cell carcinoma (SCC).

Company Info

CASTLE BIOSCIENCES INC

505 S Friendswood Drive, Suite 401

Friendswood TEXAS 77546 US

CEO: Derek J. Maetzold

Employees: 761

CSTL Company Website

CSTL Investor Relations

Phone: 18667889007

CASTLE BIOSCIENCES INC / CSTL FAQ

What is the stock price of CASTLE BIOSCIENCES INC today?

The current stock price of CSTL is 16.2 USD. The price decreased by -0.18% in the last trading session.


What is the ticker symbol for CASTLE BIOSCIENCES INC stock?

The exchange symbol of CASTLE BIOSCIENCES INC is CSTL and it is listed on the Nasdaq exchange.


On which exchange is CSTL stock listed?

CSTL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CASTLE BIOSCIENCES INC stock?

15 analysts have analysed CSTL and the average price target is 39.1 USD. This implies a price increase of 141.36% is expected in the next year compared to the current price of 16.2. Check the CASTLE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CASTLE BIOSCIENCES INC worth?

CASTLE BIOSCIENCES INC (CSTL) has a market capitalization of 467.69M USD. This makes CSTL a Small Cap stock.


How many employees does CASTLE BIOSCIENCES INC have?

CASTLE BIOSCIENCES INC (CSTL) currently has 761 employees.


What are the support and resistance levels for CASTLE BIOSCIENCES INC (CSTL) stock?

CASTLE BIOSCIENCES INC (CSTL) has a support level at 16.1 and a resistance level at 16.24. Check the full technical report for a detailed analysis of CSTL support and resistance levels.


Is CASTLE BIOSCIENCES INC (CSTL) expected to grow?

The Revenue of CASTLE BIOSCIENCES INC (CSTL) is expected to decline by -10.49% in the next year. Check the estimates tab for more information on the CSTL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CASTLE BIOSCIENCES INC (CSTL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CASTLE BIOSCIENCES INC (CSTL) stock pay dividends?

CSTL does not pay a dividend.


When does CASTLE BIOSCIENCES INC (CSTL) report earnings?

CASTLE BIOSCIENCES INC (CSTL) will report earnings on 2025-08-04, after the market close.


What is the Price/Earnings (PE) ratio of CASTLE BIOSCIENCES INC (CSTL)?

The PE ratio for CASTLE BIOSCIENCES INC (CSTL) is 31.15. This is based on the reported non-GAAP earnings per share of 0.52 and the current share price of 16.2 USD. Check the full fundamental report for a full analysis of the valuation metrics for CSTL.


What is the Short Interest ratio of CASTLE BIOSCIENCES INC (CSTL) stock?

The outstanding short interest for CASTLE BIOSCIENCES INC (CSTL) is 5.39% of its float. Check the ownership tab for more information on the CSTL short interest.


CSTL Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CSTL Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to CSTL. No worries on liquidiy or solvency for CSTL as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CSTL Financial Highlights

Over the last trailing twelve months CSTL reported a non-GAAP Earnings per Share(EPS) of 0.52. The EPS increased by 145.22% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -1.01%
ROE -1.15%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%-122.22%
Sales Q2Q%20.57%
EPS 1Y (TTM)145.22%
Revenue 1Y (TTM)38.43%

CSTL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 88% to CSTL. The Buy consensus is the average rating of analysts ratings from 15 analysts.

For the next year, analysts expect an EPS growth of -341.51% and a revenue growth -10.49% for CSTL


Ownership
Inst Owners95.85%
Ins Owners2.84%
Short Float %5.39%
Short Ratio3.22
Analysts
Analysts88
Price Target39.1 (141.36%)
EPS Next Y-341.51%
Revenue Next Year-10.49%